

**FORM 51-102F3**

**MATERIAL CHANGE REPORT**

**Item 1: Name and Address of Reporting Issuer**

Cannvas MedTech Inc. (the “**Company**”)  
804-750 West Pender Street  
Vancouver, BC V6C 2T7

**Item 2: Date of Material Change**

July 16, 2018 and July 17, 2018.

**Item 3: News Release**

News releases were disseminated and filed on SEDAR ([www.sedar.com](http://www.sedar.com)) on July 16, 2018 and July 17, 2018.

**Item 4: Summary of Material Changes**

On July 16, 2018, the Company and Natures Hemp Inc. (“**Natures Hemp**”) announced the signing of a letter of intent (“**LOI**”), to negotiate, in good faith, a data analytics agreement.

On July 17, 2018, the Company announced the appointment of Radu Puscasu as Data Protection Officer.

Additionally, on July 17, 2018, the Company also announced its intention to expand into Germany, one of the fastest growing medical cannabis marketplaces in the world.

**Item 5: Full Description of Material Change**

On July 16, 2018, the Company and Natures Hemp announced the signing of a LOI, to negotiate, in good faith, a data analytics agreement, for which the Company will provide industry insight and analytical model capabilities to Natures Hemp business models and Key Performance Indicators (KPIs).

Under the terms of the Agreement, the Company will develop specific parameters within its existing Cannvas Data framework to collect data and analytics from Natures Hemp and their strategic partnerships, and Natures Hemp gains access to a broad data set as they press forward in the hemp sector and become a stand-alone public company. This agreement will allow Natures Hemp to bring the right products to market, at the right time, to the right individuals that will maximize Natures Hemp customer conversion funnel.

Cannvas Data is the analytics branch of the Company. Its mission is to collect data from various credible sources to enhance user persona data algorithms for Cannvas.me. Cannvas Data will leverage existing databases, site traffic and advanced technology for marketing purposes, and will leverage its comprehensive solution for the global hemp community. The companies have agreed to a discovery period whereby the technological specifications of the connectivity will be setup by Cannvas Data, and will work together towards a definitive partnership agreement within the next 45 days.

The letter of intent between the two companies comes after a wide-ranging agriculture and food policy legislation known as the Farm Bill, passed in the U.S. Senate by a vote of 86 - 11 on June 28, 2018. The Bill contains provisions to legalize the cultivation, processing and sale of industrial hemp. In April, Senate Majority Leader Mitch McConnell (R-KY) introduced standalone legislation to legalize hemp and make hemp plants eligible for crop insurance, the Hemp Farming Act, which were included in the larger Farm Bill. If and when receiving final approval, the non-psychoactive form of cannabis would finally become legal to grow in the United States after a long absence.

**About Natures Hemp Inc.**

Natures Hemp is a wholly owned subsidiary of PUF Ventures Inc. (CSE: PUF). On April 4, 2018 PUF announced a plan of arrangement to spin-out Natures Hemp to create a standalone, publicly listed company on the Canadian Stock Exchange.

Natures Hemp is a biotechnology and consumer products company focused on unlocking the true value of hemp and developing a new generation of plant-based, nutrient rich cannabidiol (“**CBD**”) food, beverage and healthcare related products. It is establishing its own farms to produce high quality organic hemp plants and using a proprietary extraction technology to produce legal hemp fibers and CBD extract. It is also launching a premium brand of quality CBD products with an emphasis on health and wellness.

On July 17, 2018, the Company announced the appointment of Radu Puscasu as Data Protection Officer. With over 14 years of experience, Radu has been heavily involved in creating meaningful customer relationship experiences through secure technology. He has held senior roles at Bell Media, TD Bank Securities (Equity Derivative Solutions and Data Management Services), and Pitney Bowes and has worked with client companies such as Takeda, AstraZenaca, Pfizer, and Novartis.

The Company is also pleased to announce its intention to expand into Germany, one of the fastest growing medical cannabis marketplaces in the world. The country has fully embraced medical cannabis as a legitimate, doctor-prescribed, insurance-paid, and pharmacy-provided medical and healthcare product.

With significant potential to improve the health and wellness of patients worldwide, the Cannvas.me platform will allow for global interaction of patients and consumers to medical practitioner and licensed producers. In January 2017, Germany fully embraced the medical benefits of cannabis and approved the substance as a legitimate, doctor-prescribed, pharmacy-provided, and perhaps most importantly insurance-paid, pharma product. As the most populous member of the 28 country European Union, Germany’s population of 82 million people accounts for 16% of the total population and 28% of the euro area economy, and represents a significant market opportunity for Cannvas.

#### **About Cannvas MedTech Inc.**

Cannvas MedTech is a leading business technology company within the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

**Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**Item 7: Omitted Information**

None.

**Item 8: Executive Officer**

For further information, please contact:

Investor Relations  
[ir@cannvasmedtech.com](mailto:ir@cannvasmedtech.com)  
 1-800-489-0116

**Item 9: Date of Report**

July 17, 2018.